Enanta Pharmaceuticals, Inc.

NasdaqGS:ENTA Stock Report

Market Cap: US$422.5m

Enanta Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ENTA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
05 Dec 25SellUS$4,596Kathleen CappsIndividual323US$14.23
05 Dec 25SellUS$67,493Jay LulyIndividual4,743US$14.23
05 Dec 25SellUS$34,010Yat OrIndividual2,390US$14.23
05 Dec 25SellUS$29,968Tara KiefferIndividual2,106US$14.23
05 Dec 25SellUS$19,837Brendan LuuIndividual1,394US$14.23
05 Dec 25SellUS$11,356Scott RottinghausIndividual798US$14.23
05 Dec 25SellUS$7,713Harry TroutIndividual542US$14.23
02 Dec 25SellUS$5,305Harry TroutIndividual380US$13.96
02 Dec 25SellUS$2,890Kathleen CappsIndividual207US$13.96
12 Feb 25BuyUS$256,050Jay LulyIndividual45,000US$5.69

Insider Trading Volume

Insider Buying: ENTA insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ENTA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies19,1650.0664%
Individual Insiders1,284,7364.45%
VC/PE Firms1,484,5135.14%
General Public2,551,9938.84%
Hedge Funds4,236,70614.7%
Institutions19,285,48866.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 36.2%.

Top Shareholders

Top 25 shareholders own 82.14% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
22.4%
Janus Henderson Group plc
6,453,593US$94.5m231%0.03%
7.35%
Farallon Capital Management, L.L.C.
2,122,262US$31.1m0%0.15%
7.33%
Krensavage Asset Management, LLC
2,114,444US$31.0m0%11.43%
6.72%
The Vanguard Group, Inc.
1,938,829US$28.4m-1.91%no data
6.35%
BlackRock, Inc.
1,832,980US$26.8m-0.75%no data
5.14%
Deep Track Capital, LP
1,484,513US$21.7m0%0.4%
3.28%
Millennium Management LLC
948,084US$13.9m-35%0.01%
3%
Acadian Asset Management LLC
867,037US$12.7m0%0.02%
2.86%
Jay Luly
826,526US$12.1m-0.02%no data
2.77%
Commodore Capital LP
800,000US$11.7m0%0.4%
1.71%
Geode Capital Management, LLC
493,194US$7.2m1.52%no data
1.66%
Renaissance Technologies LLC
479,600US$7.0m2.15%0.01%
1.64%
State Street Global Advisors, Inc.
471,992US$6.9m0.37%no data
1.27%
Yat Or
366,142US$5.4m1.05%no data
1.22%
Point72 Asset Management, L.P.
350,722US$5.1m0%0.01%
1.06%
Stonepine Capital Management LLC
305,000US$4.5m-49.5%1.97%
0.95%
Marshall Wace LLP
275,389US$4.0m-67.9%no data
0.94%
Dimensional Fund Advisors LP
270,068US$4.0m-2.73%no data
0.78%
D. E. Shaw & Co., L.P.
225,744US$3.3m-20%no data
0.75%
AQR Capital Management, LLC
216,231US$3.2m-43.8%no data
0.68%
Northern Trust Global Investments
195,896US$2.9m-22%no data
0.59%
Eaton Vance Management
169,646US$2.5m-0.94%no data
0.59%
Jacobs Levy Equity Management Inc
169,048US$2.5m-12%0.01%
0.58%
Charles Schwab Investment Management, Inc.
166,547US$2.4m1.15%no data
0.57%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
163,138US$2.4m277%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/10 02:33
End of Day Share Price 2025/12/09 00:00
Earnings2025/09/30
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Enanta Pharmaceuticals, Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Geoffrey MeachamBarclays
Patrick TrucchioBerenberg